CNR1 and early-onset autosomal dominant Alzheimer disease: A similar scenario occurs in Alzheimer’s disease mouse models, in which CB1R pharmacological activation produces a therapeutic benefit and CB1R genetic deletion worsens the disease (Aso et al, 2012, 2018).